Next Article in Journal
The Opportunities and Challenges of Peroxisome Proliferator-Activated Receptors Ligands in Clinical Drug Discovery and Development
Next Article in Special Issue
Immunological Heterogeneity of Healthy Peripheral Blood Stem Cell Donors—Effects of Granulocyte Colony-Stimulating Factor on Inflammatory Responses
Previous Article in Journal
Nano/Micro-Assisted Regenerative Medicine
Previous Article in Special Issue
Diverging Concepts and Novel Perspectives in Regenerative Medicine
Review

Mesenchymal Stem Cell Expressing TRAIL as Targeted Therapy against Sensitised Tumour

1
Stem Cell Laboratory, Haematology Unit, Cancer Research Centre, Institute for Medical Research, Kuala Lumpur 50588, Malaysia
2
UPM-MAKNA Cancer Research Laboratory, Institute of Bioscience, Universiti Putra Malaysia, Serdang 43400, Selangor, Malaysia
3
Medical Genetics Laboratory, Department of Biomedical Sciences, Faculty of Medicine & Health Sciences, Universiti Putra Malaysia, Serdang 43400, Selangor, Malaysia
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Int. J. Mol. Sci. 2018, 19(8), 2188; https://doi.org/10.3390/ijms19082188
Received: 13 June 2018 / Revised: 30 June 2018 / Accepted: 2 July 2018 / Published: 27 July 2018
(This article belongs to the Special Issue Advances in Cell Transplantation 2019)
Tapping into the ability of engineered mesenchymal stem cells (MSCs) to mobilise into the tumour has expanded the scope of cancer treatment. Engineered MSCs expressing tumour necrosis factor (TNF)-related apoptosis inducing ligand (MSC-TRAIL) could serve as a platform for an efficient and targeted form of therapy. However, the presence of cancer stem cells (CSCs) that are resistant to TRAIL and apoptosis may represent a challenge for effective treatment. Nonetheless, with the discovery of small molecular inhibitors that could target CSCs and tumour signalling pathways, a higher efficacy of MSC-TRAIL mediated tumour inhibition can be achieved. This might pave the way for a more effective form of combined therapy, which leads to a better treatment outcome. In this review, we first discuss the tumour-homing capacity of MSCs, its effect in tumour tropism, the different approach behind genetically-engineered MSCs, and the efficacy and safety of each agent delivered by these MSCs. Then, we focus on how sensitisation of CSCs and tumours using small molecular inhibitors can increase the effect of these cells to either TRAIL or MSC-TRAIL mediated inhibition. In the conclusion, we address a few questions and safety concerns regarding the utilization of engineered MSCs for future treatment in patients. View Full-Text
Keywords: mesenchymal stem cells; TRAIL; apoptosis; sensitisation; cancer stem cells; tumours mesenchymal stem cells; TRAIL; apoptosis; sensitisation; cancer stem cells; tumours
Show Figures

Graphical abstract

MDPI and ACS Style

Shaik Fakiruddin, K.; Ghazalli, N.; Lim, M.N.; Zakaria, Z.; Abdullah, S. Mesenchymal Stem Cell Expressing TRAIL as Targeted Therapy against Sensitised Tumour. Int. J. Mol. Sci. 2018, 19, 2188. https://doi.org/10.3390/ijms19082188

AMA Style

Shaik Fakiruddin K, Ghazalli N, Lim MN, Zakaria Z, Abdullah S. Mesenchymal Stem Cell Expressing TRAIL as Targeted Therapy against Sensitised Tumour. International Journal of Molecular Sciences. 2018; 19(8):2188. https://doi.org/10.3390/ijms19082188

Chicago/Turabian Style

Shaik Fakiruddin, Kamal, Nadiah Ghazalli, Moon N. Lim, Zubaidah Zakaria, and Syahril Abdullah. 2018. "Mesenchymal Stem Cell Expressing TRAIL as Targeted Therapy against Sensitised Tumour" International Journal of Molecular Sciences 19, no. 8: 2188. https://doi.org/10.3390/ijms19082188

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop